|
|
||||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
Natural killer cells are
innate effector cells serving as a first line of defense against certain
viral infections and tumors. Natural killer cells have the ability
to recognize and kill a variety of different tumor types using specific cell
surface receptors to recognize tumors. These activating NK cell receptors
that recognize tumor cells have been identified in mice and humans natural
killer cells. Dartmouth researchers have now
found that a chimeric NK receptor molecule composed of a natural killer cell
receptor (e.g., a C-type lectin-like NK cell receptor) and an immune
signaling receptor (e.g., a CD3-zeta or Fc epsilon receptor-gamma
chain) expressed on the surface of a T cell can facilitate killing of a tumor
cell and production of proinflammatory cytokines. The chimeric receptor
molecules provide a means for the patient’s own immune cells to
recognize and activate anti-tumor immunity and establish long-term, specific,
anti-tumor responses. Accordingly, the chimeric receptor molecules are useful
for treating tumors or preventing growth of dormant or residual tumor cells.
The initial findings have been published in the journal Blood (Zhang
et al. 106:1544 (2005)). This technology is claimed in
the published PCT Application No. PCT/US2005/031100 and the published United
States Patent Application No. 12/407,440. We are seeking an industrial
partner interested in its commercialization. (Ref: J267) |
||
|
|
|
|
|
|
|
|
|
«Technology Transfer Office : Sponsored Projects : Dartmouth College |
||
|
|
||||
|
11 Rope Ferry Road #6210 |
||||
|
Hanover, NH 03755-1404 |
Phone: (603) 646-3027 |
|||
|
|
|
|
Fax: (603) 646-3670 |
|
